NRP2 acts as a risk factor for patients with BRCA, HNSC, KIRP, LUAD, PAAD and STAD, and as a protective factor for patients with LIHC and UCEC (Figure 3A). This evidence concerns the gene NRP2 and gastric adenocarcinoma.